Article info
Original research
Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy
- Correspondence to Dr Ielizza Desideri, UO Farmaceutica - Politiche del Farmaco, Pisa University Hospital, Pisa 56126, Italy; i.desideri{at}ao-pisa.toscana.it
Citation
Lopinavir/ritonavir, a new galenic oral formulation from commercial solid form, fine-tuned by nuclear magnetic resonance spectroscopy
Publication history
- Received May 28, 2020
- Revised October 28, 2020
- Accepted November 5, 2020
- First published November 19, 2020.
Online issue publication
August 23, 2022
Article Versions
- Previous version (19 November 2020).
- You are viewing the most recent version of this article.
Request permissions
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Copyright information
© European Association of Hospital Pharmacists 2022. No commercial re-use. See rights and permissions. Published by BMJ. This article is made freely available for personal use in accordance with BMJ’s website terms and conditions for the duration of the covid-19 pandemic or until otherwise determined by BMJ. You may use, download and print the article for any lawful, non-commercial purpose (including text and data mining) provided that all copyright notices and trade marks are retained.https://bmj.com/coronavirus/usage